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combined with the detection of specific antibodies anti-Toxoplasma gondii
IgM, IgG, IgA on serum or CSF. The specific therapy was differentiated,
using the triple combination pirymethamine/sulfadoxine/corticosteroids, or
pirymethamine/clarithromycine/corticosteroids and, the double combina-
tion of azithromycine/corticosteroids in patients with malignancies. The
results were very good being necessary 1 to 3 courses of treatment, without
relapses. There were no side effects noticed.
CondU51ons: Pirymethamine remains the first choice treatment in ocular
toxoplasmosis, with a good tolerance and very good eye penetration but, in
cases when the drug is contra-indicated, azithromycine seems to be the
alternative.
IWeP333[ Detection of Cryptosporidium oocysts as an enteric
pathogen in immunocompromised patients
A. Yetkinl , F. Aktas2, D. Arman2
Department ofClinical MicrobiolflY and Infectious Diseases of I Ankara
Trailling ami Research Hospital; Gazi University School ofMedicine, Ankara,
Turkey
[n this study, the detection rate Cryptosporidium as a causative agent in
diarrheic immunosuppressed patients who have either hematologic malig-
nancy or solid tumor, is evaluated. For this purpose, three groups; Group [,
group II, group III were formed which consisted of diarrheic immunosup-
presed patients, nondiarrheic immunosuppresed patients and diarrheic
immunocompetent patients respectively. [mmunoflurescence antibody
method was used for the detection of Cryptosporidium oocysts. A total
number of 96 fecal samples were examined, in which seven of them were
positive for Cryptosporidium oocysts. Cryptosporidium was detected six of34
(17.64%) diarrheic immunosuppresed patients and one of 30 (3.33%)
diarrheic immunocompetent patients and none in nondiarrheic immuno-
suppresed patients. The detection rate ofCryptosporidium as a causative agent
among diarrhic patients (group I, group III) is found insignificant (OR =
6.21, CI = 0.66-145.95) where as among immunsuppresed patients (group
I, group II), it is found statistically significant (p < 0.05). As a conclusion
Cryptosporidium may be a causative agent in diarrheic immunosuppressed
patients other than AIDS.
IWeP334! Urinary tract infections (UTls) in patients
undergoing high dose chemotherapy (HDCh) With auto-PBPC
transplantation
E. Mroz, K. Kuzko, G. Mokracka-Latajka, A. Seniuk, A. Lange
Dept. ofMicrobiology, Medical University, BMT Unit ofK. Dluski, Hospitall
Inst. of Immun. and Exp. Therapy, Wroclaw, Poland
Objectives: The purpose of this study was to determine the frequency
(UTIs) in patients (pts) undergoing HDCh with peripheral blood progenitor
cell transplantation (pBPCn.
Methods: 106 pts were transplanted from 1993 until 1997. Forty-nine pts
suffered from solid tumors (19 females and 30 males) and 57 from hemato-
logical malignancies (27 females and 30 males). 77 pts underwent single, 20
tandem and 9 triple courses ofHDCh with PBPCT. Microbiological check-
up covered the period from -30 until + 30 day after PBPCT. Samples of
middle stream urine were inoculated onto McConkey, blood agar and
Sabouraud agar with using of calibrated loops. Identification of strains was
carried out with using by the ATB System (bioMerieux, France). Significant
UTI was considered when more than 1()()()() CFUIml ofurine was observed.
Pts after HDCh with PBPCT showed profound neutropoenia lasting from
one to two weeks after PBPCT and immunosuppression. All of them were
given nonabsorbable antibiotics.
Results: UTIs were observed in 42 out ofl06 (40%) pts. In 5 cases the UTI
was appear before, in 21 cases after and in 16 cases before and after PBPCT.
UTls were seen more frequently during the first and the second week (in 16
and in 12 pts, respectively) than during the third and fourth week (in 6 and 3
pts, respectively) after PBPCT. UTIs were more frequent in females than in
males (50% vs 32%). Isolated pathogens: E coli, Enterobactniaceae, Gram-
positive bacilli, fungi and others. UTIs were caused by single microorgan-
isms or were polymicrobial.
Conduslons: UTIs were observing mmr1y during the nemropoenic period.
Females were more susceptible than males.
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IMo13-11 Clinical failures: The tip of the iceberg?
J. Garau
H05pital Mutua de Terra5sa, University ofBarcelona, Spain
In pneumococcal meningitis, resistance in StreptocoCCU5 pneumoniae compro-
mises clinical outcome. However, the clinical impact ofincreasing resistance
on community-acquired respiratory tract inf«'tions (RTis) is less clear.
Clinical efficacy of antibiotics is related to bacteriological outcome
(Dagan et el. Pediatr Infect Dis] 1998;17:776-782), which is influenced by
the pharmacodynamic activity (potency and pharmacokinetics) ofthe agent
against the infecting pathogen. For example, in S. pneumoniae-related acute
otitis media, the bacteriological failure rate of cefaclor and cefuroxime
increa,e, as the minimum inhibitory concentration (MIC) against the
pathogen increases (Dagan et al. Pediatr Infect Dis J 1998;15:980-985).
Macrolide resistance in S. pneumoniae also results in bacteriological failure
in this model (Dagan et al. Antimicrob Agents Chemother 2000:44:43-50).
Surveillance ofclinical isolates from community-acquired R Tis shows that
there i, a trend towards increasing prevalence ofresistant pathogens, and that
the MICs among't these resistant isolates are increasing for a range ofagents.
Emerging data suggest tibet resistance is compromising the efficacy of
routinely used antibacterial agents, for example, reports of clinical and
bacteriological failure ofmacrolides due to tesistance in S. pneumoniae (Garau
et al. ICMAS, 2000, abstract 7.09), and offluoroquinolones in patients with
community-acquired pneumonia.
The results from a number of published clinical trials appear to suggest
that resistance has not significantly compromised the clinical outcome of
routinely used agents. However, these published studies often exclude from
the analysis patients most likely to be infected with resistant pathogens, or
were conducted prior to the current extent of resistance. Recent retro-
spective analyses and increasing sporadic reports of clinical failure due to
resistance may be more reflective ofthe real situation and show the 'tip ofthe
iceberg'. These reports suggest a need to reassess current empiric therapeutic
recommendations for the treatment of community-acquired R TI suspected
to be of pneumococcal etiology.
[Mo13=2j Steering an appropriate course; Principles to guide
antibiotic choice
O. Cars
Swedish Institutefor I"fectious Disease Control, Solna, Sweden
The prevalence and degree of resistance in common R TI pathogens is, in
general, increasing worldwide. Although the health impact of resistance is
not yet fully understood, it is postulated that once the impact is measurable, it
may be too late to apply interventions to reduce resistance levels and regain
previous quality and cost of care. This raises the question of whether, and
how, we should address resistance now, before patient care is irreversibly
compromised.
The association between antibiotic consumption and the prevalence of
resistance is widely assumed. However, evidence suggests that reduction~
consumption may not be the only, or most effective, way ofreduc~
prevalence of resistance. Mathematical modeling to predict the long-tern.
effects of antibiotic consumption on resistance shows that the timescale for
the emergence ofresistance is typically shorter than the decay time following
a decline in antibiotic consumption. Increasing evidence suggests that
bacteria acquire 'compensatory genes', which reduce the fitness cost of
resistance and, therefore, the benefit of losing resistance mechanisms in the
absence ofantibiotics. Co-selection of multi-resistant bacteria by any agent
to which they are resistant suggests that even if overall consumption of
antibiotics is reduced, continued use of agents that select for co-resistances
could counteract the desired positive effects. Against this background a
general principle is proposed: not only should antibiotics not be used where
unnecessary or inappropriate, bur also, if antibiotic therapy is deemed
necessary, the agent used should be appropriate. The guiding principle for
appropriate prescribing is to maximize patient outcome whilst minimizing
the potential for selection and spread of resistance by using agents with
sufficient pharmacodynamics (potency and pharmacokinetics) to elicit rapid
eradication of the bacterial population, including emerging resistant
mutants, from the infection site. Whilst the choice of agent may not be
the same in all regions and will depend on local resistance trends and disease
aetiology. the application of these principles may help to preserve the
benefits of antibiotic therapy.
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IMo13-31 Re-evaluating current antibiotic therapy
W. A. Craig
University of Wisconsin, Madison, WI, United States
Pharmacokinetic/pharmacodynamic (PK/PD) parameters derived from
animal and clinical infection models have been shown to be excellent
predictors ofbacteriologic efficacy. For example, in otitis media and sinusitis,
a high rate ofbacteriologic cure is obtained when serum concentrations of{3-
lactams and several macrolides exceed the MIC ofthe infecting pathogen for
at least 40% ofthe dosing interval. Likewise, the 24-hour AUC/MIC ratio is
a good predictor of bacteriologic and clinical efficacy for azithromycin in
otitis media and f1uoroquinolones in bacterial pneumonia.
The value of PK/PD relationships has been recognized by the National
Committee for Clinical Laboratory Standards (NCCLS) as another impor-
t:mt factor to consider when establishing susceptibility breakpoint'. Recent
breakpoints with oral {3-lactams and new f1uoroquiolones for Streptococcus
pneumoniae reflect the impact of PK/PD relationships.
Many of the same PK/PD parameters appear to be important in reducing
the emergence ofresistant organisms, Peak/MIC and AUC/MIC parameters
have been important for f1uoroquinolones. However, different f1uoroqui-
nolones may have different mutation prevention concentrations. Prolonged
durations above the MIC appear to be important for {3-laetams and
macrolides to reduce the potential for resistance development and eliminate
resistant clones of S. pneumoniae from the nasopharynx.
In an era of increasing resistance, we should select agents and doses that
provide drug concentrations that exceed the magnitude of the PK/PD
parameter required for efficacy and prevention of resistance.
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ITu19-11 MYSnC (Meropenem Yearly Susceptibility Test
Information Collection): Trends in resistance
R. N.]ones
University of Iowa College ofMedicine/CAST Laboratories, Iowa, United
States
Objectives: To describe the MYSTIC antimicrobial surveillance system and
its results during three years of operation.
Methods: Since 1997, the MYSTIC programme has assessed the activity of
meropenem and other broad spectrum antimicrobial agents on significant
bacterial strains. Bacteria ~cre collected in ho~pital" or ,;,pecific service units
which were using meropenem. Meropenem was compared with imipenem,
ceftazidime, cefepime, piperacillin/tazobactam, ciprofloxacin, gentamicin or
tobramycin using reference quality methods (NCCLS agar dilution or broth
microdilution). Procedures were also performed to detect extended spec-
trum beta-Iactamases and other inactivating enzymes.
Results: Initial baseline studies were reported from 47 centres in Europe,
Brazil, Mexico and the US. No escalated carbapenem resistance was
detected, but resistance to newer cephalosporins, aminoglycosides, cipro-
f1oxacin, and piperacillin/tazobactam was shown to have increased in most
geographic areas sampled. Meropenem was generally more active than
imipenem against Gram-negative bacilli but slightly less active against
Gram-positive cocci, e.g. Enterococcus faecalis (MIC90, 16-32 ILg/mL).
Pseudomonas aeruginosa isolates from the cystic fibrosis centres were pre-
dictably less susceptible to meropenem than those from intensive care unit,
hospital or neutropenic centres (MIC90, 32 vs. 4-8 ILg/mL); however
meropenem remained somewhat more potent than imipenem.
Conclusions: Results from the MYSTIC study indicate the continued in
vitro potency ofmeropenem against pathogens isolated in Europe, Latin and
North America. Emergence ofcarbapenem-resistant strains remains at a low
and stable level indicating that carbapenems continue to be a reliable option
for serious clinical infections. This is in contrast to other antibiotics tested
where some high level resistance was seen.
ITuI9-2! Gram-negative resistance: What do we do?
D. L. Paterson
Instituto lWediterraneo per i Trapianti e Terapie ad Alta Specializzazione
(ISMETT), Palermo, Italy
In contrast to the attention paid to Gram-positive resistance, recent increases
in the resistance of Gram-negative bacilli to antibiotics have not been
matched by the development of new antibiotics. Resistant isolates of
Klebsiella species producing extended-spectrum beta-lactamases (ESBLs)
were detected within months of the commercial release of the third-
generation cephalosporins. Apart from rare case reports. in vitro studies
show 100% susceptibility of these isolates to the carbapenems, with
meropenem consistently more active than imipenem. In contrast, approxi-
mately 20% of these ESBL-producing isolates are resistant to quinolones or
cefepime and resisunce to beta-Iactamfbeta-Iacumase inhibitor combina-
tions is seen even more frequendy. Clinical findings mirror these results,
with the carbapenems being consistently associated with positive clinical
outcome for serious infections. Carbapenems are also stable to chtomoso-
mally-mediated beta-lactamases produced by isolates such as Enterobacter
cloacae, and are a first-line treatment for serious infections caused by these
organisms. Quinolones and aminoglycosides are other options. Third-
generation cephalosporins should not be used to treat these organisms or
ESBL-producing isolates, regardless of their apparent in vitro susceptibility.
Acinetobacter species. Pseudomonas aeruginosa and Stenotrophomf»las maltophiUa
are other Gram-negative organisms that are increasingly being encountered
with resistance to multiple antibiotics. Unfortunately, we have entered the
new millennium with pessimism regarding our ability to treat multiply-
resistant Gram-negative isolates. At present, we must optimise our use of
existing effective compounds (e.g. the carbapenems) for first-line therapy in
patients with difficult-to-treat infections. and utilise strategies to prevent the
spread of resistant organisms within our hospitals.
ITu19-3 IVentilator-associated pneumonia: Dealing with
resistance
J. Garau
Hospital Mutua de Terrassa, Barcelona, Spain
Ventilator-associated pneumonia (VAP) is a prevalent condition frequently
caused by Gram-negative bacteria. VAP is associated with high morbidity
and mortality and prolonged hospitalisation, and therefore requires prompt
and effective first-line treatment. Increasing resistance in Gram-negative
organisms to commonly prescribed antibiotics means that choosing the right
first-line antimicrobial therapy for VAP is becoming more difficult. In a
recent study, resistance to the prescribed third-generation cephalosporin
(ceftazidime or ceftriaxone) was the most common reason for changing the
initial regimen in patients with VAP. Carbapenems have a broad spectrum
of antimicrobial activity and are active against bacteria resistant to other
beta-lactam antibiotics, including cephalosporins. In a recent prospective,
randomised study specifically focussed on YAP (the Spanish Collaborative
Group for the Study ofSevere Infections), meropenem (1 g iv every 8 h) was
more effective clinically (49/59 [83%)) than ceftazidime plus amikacin (39/59
[66%); P = 0.035). The most common causative pathogens in this study
were Gram-negative aerobes (Pseudomonas aeruginosa, Haemophilus injluen-
zae and enteric bacteria being the most prevalent). Thus, as there are few
antimicrobial agents either currently available or in clinical development
that can combat life-threatening multiply-resistant Gram-negative patho-
gens, the carbapenems, for example meropenem, should be considered as a
first-line empirical therapy for this indication.
ITuI9-41 Gram-positive resistance: What do we do?
R. C. Moellering
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Antimicrobial resistance is a serious threat to the clinical effectiveness of
antibiotics, particularly for infections caused by Gram-positive cocci.
Selective pressure from extensive antimicrobial use is the major factor
leading to resistance. Whilst the implementation of infection control
techniques and the appropriate use of available agents are vital, they are
failing to stem the tide of antimicrobial resistance. Several new approaches
are being taken to develop novel agents with activity against multi-resistant
Gram-positive bacteria. One approach is the re-examination of agents
previously limited by administration difficulties or toxicity. For example,
the streptogramin combination, quinupristin/dalfopristin, has been recently
introduced only as an intravenous formulation suitable for treating seriously
ill patients. Alternative methods of administration of daptomycin and
ramoplanin may overcome limitations due to toxicity. The favourable
activity of everninomicin has been known for several decades and a new
parenteral formulation is now being tested. The oxazolidinones represent a
completely new class of agent which inhibit protein synthesis by a novel
